Augmedix Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-19.17	-24.45	-17.46	-15.6	-18.5	-24.16
Depreciation & Amortization	2.14	1.53	0.69	0.87	0.95	1.59
Share-Based Compensation	2.47	2.11	1.39	0.67	0.4	0.25
Other Operating Activities	-0.88	4.04	-3.21	-0.33	2.51	2.43
Operating Cash Flow	-15.44	-16.77	-18.59	-14.4	-14.65	-19.89
Capital Expenditures	-3.11	-1.41	-0.61	-0.65	-0.82	-0.34
Investing Cash Flow	-3.11	-1.41	-0.61	-0.65	-0.82	-0.34
Share Issuance / Repurchase	38.42	0.03	36.05	24.34	0	0.01
Debt Issued / Paid	4.95	-1.27	1.78	2.13	1.89	1.32
Other Financing Activities	-	-	-	-0.05	15.27	20.82
Financing Cash Flow	43.37	-1.24	37.83	26.42	17.17	22.15
Exchange Rate Effect	-0.47	-0.18	-0.01	-0	-0.01	0
Net Cash Flow	24.35	-19.6	18.61	11.37	1.69	1.91
Free Cash Flow	-18.55	-18.18	-19.2	-15.05	-15.47	-20.24
Free Cash Flow Margin	-41.35%	-58.78%	-86.64%	-91.28%	-109.65%	-187.11%
Free Cash Flow Per Share	-0.42	-0.49	-0.66	-2.14	-18.60	-17.01

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).